Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background The most suitable antihypertensive drug to reduce the risk of cardiovascular disease in patients with hypertension and diabetes is unclear. In prespecified analyses, we compared the effects of losartan and atenolol on cardiovascular morbidity and mortality in diabetic patients.Methods As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment. Mean age of patients was 67 years (SD 7) and mean blood pressure 177/96 mm Hg (14/10) after placebo run-in. We followed up patients for at least 4 years (mean 4.7 years [1.1]). We used Cox regression analysis with baseline Framingham risk score and electrocardiogram-LVH as covariates to compare the effects of the drugs on the primary composite endpoint of cardiovascular morbidity and mortality (cardiovascular death, stroke, or myocardial infarction).Findings Mean blood pressure fell to 146/79 mm Hg (17/11) in losartan patients and 148/79 mm Hg (19/11) in atenolol patients. The primary endpoint occurred in 103 patients assigned losartan (n=586) and 139 assigned atenolol (n=609); relative risk 0.76 (95% CI 0.58-.98), p=0.031. 38 and 61 patients in the losartan and atenolol groups, respectively, died from cardiovascular disease; 0.63 (0.42-0.95), p=0.028. Mortality from all causes was 63 and 104 in losartan and atenolol groups, respectively; 0.61 (0.45-0.84), p=0.002.Interpretation Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes, and LVH. Losartan seems to have benefits beyond blood pressure reduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All available BP-lowering drugs can be used, but evidence strongly supports using a renin-angiotensin system (RAS) inhibitor (ACE-I, ARB), particularly in patients with evidence of end-organ damage (albuminuria and left ventricular [LV] hypertrophy).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [213]
In the citing paper
“In patients with congestive heart failure (CHF), including diabetic subgroups, ARBs have been shown to reduce major CVD outcomes (175–178), and in type 2 patients with significant nephropathy, ARBs were superior to calcium channel blockers for reducing heart failure (179–181).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [178]
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Self-citationDahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citationStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
(2000) · PubMed · Cited by 2,095
Research works printed but not linked: 2
- Liu, 2000, Cardiovascular disease and prognosis in adults with glucose disorders: the Strong Heart Study, J Am Coll Cardiol, 35, 263A
- 2002, Diabetic nephropathy, Diabetes Care, 25, S85
Cited by
Items 501–600 of 1,001
Learning from large cardiovascular clinical trials: Classical cardiovascular risk factors
Kempler, P. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.005 · Cited by 28
Under-prescribing of cardiovascular therapies for diabetes in primary care
Bennett, K., Williams, D. J., & Feely, J. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0542-6 · Cited by 29
Kurokawa, K., Chan, J. C. N., Cooper, M. E., Keane, W. F., Shahinfar, S., & Zhang, Z. (2006) · Clinical and Experimental Nephrology · doi:10.1007/s10157-006-0427-6 · Cited by 29
Boersma, C., Thobari, J. A., Gansevoort, R. T., den Berg, L. T. W. D. J., de Jong, P. E., de Zeeuw, D., Annemans, L., & Postma, M. J. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624060-00001 · Cited by 27
Havranek, E. P., Esler, A. L., Estacio, R. O., Mehler, P. S., & Schrier, R. W. (2003) · American Heart Journal · doi:10.1016/s0002-8703(02)94780-0 · Cited by 29
Basile, J., Lackland, D. T., Basile, J. M., Riehle, J. E., & Egan, B. M. (2004) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2004.02665.x · Cited by 31
Weinberg, M. S., Kaperonis, N., & Bakris, G. L. (2003) · Current Hypertension Reports · doi:10.1007/s11906-003-0088-8 · Cited by 28
Hughes, D. B., & Britton, M. L. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.11.1602 · Cited by 28
Doença cardiovascular no diabetes mellitus: análise dos fatores de risco clássicos e não-clássicos
Siqueira, A. F. A., de Almeida-Pititto, B., & Ferreira, S. R. G. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000200014 · Cited by 79
Is chronic diabetic foot ulcer an indicator of cardiac disease?
Löndahl, M., Katzman, P., Fredholm, O., Nilsson, A., & Apelqvist, J. (2008) · Journal of Wound Care · doi:10.12968/jowc.2008.17.1.27915 · Cited by 27
Saunders, E., Cable, G., & Neutel, J. (2008) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2007.07195.x · Cited by 28
Optimizing Therapy in the Diabetic Patient with Renal Disease: Antihypertensive Treatment
Deferrari, G., Ravera, M., Berruti, V., Leoncini, G., & Deferrari, L. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000105881.71167.44 · Cited by 29
Beta-Blockers and Diabetes: The Bad Guys Come Good
Cruickshank, J. M. (2002) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1022146721098 · Cited by 31
Sica, D. A. (2003) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2003.02836.x · Cited by 27
The renin angiotensin system as a therapeutic target to prevent diabetes and its complications
Vijayaraghavan, K., & DEEDWANIA, P. C. (2005) · Cardiology Clinics · doi:10.1016/j.ccl.2004.11.003 · Cited by 24
The Pathogenesis and Management of Hypertension in Diabetic Kidney Disease
Buren, P. N. V., & Toto, R. D. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.10.003 · Cited by 30
Effect of Combined Treatment With Curcumin and Candesartan on Ischemic Brain Damage in Mice
Awad, A. S. (2010) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2010.03.008 · Cited by 27
Franklin, S. S., Wachtell, K., Papademetriou, V., Olsen, M. H., Devereux, R. B., Fyhrquist, F., Ibsen, H., Kjeldsen, S. E., & Dahlöf, B. (2005) · Hypertension · doi:10.1161/01.hyp.0000179604.42845.8d · Cited by 27
Self-citationOng, H. T. (2009) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2009.06.090094 · Cited by 28
Diabetes in the elderly and in women: cardiovascular risks
Sowers, J. R. (2004) · Cardiology Clinics · doi:10.1016/j.ccl.2004.06.008 · Cited by 30
Breath holding index in detection of early cognitive decline
Zavoreo, I., Kes, V. B., Morović, S., Šerić, V., & Demarin, V. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.08.062 · Cited by 25
Latin American consensus on diabetes mellitus and hypertension
Burlando, G., nchez, R. A. S., Ramos, F. H., Mogensen, C. E., & Zanchetti, A. (2004) · Journal of Hypertension · doi:10.1097/00004872-200412000-00001 · Cited by 31
Lassila, M., Davis, B. J., Allen, T. J., Burrell, L. M., Cooper, M. E., & Cao, Z. (2003) · Clinical Science · doi:10.1042/cs1040341 · Cited by 25
Treatment of the Patient With Diabetes Mellitus and Risk of Nephropathy
Hollenberg, N. K. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.2.125 · Cited by 25
Zimmermann, M., & Unger, T. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.5.1201 · Cited by 26
Ambrose, J. A., & D’Agate, D. J. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.09.037 · Cited by 27
Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients
Ceriello, A., Assaloni, R., Da Ros, R., Maier, A., Quagliaro, L., Piconi, L., Esposito, K., & Giugliano, D. (2004) · Diabetologia · doi:10.1007/s00125-004-1487-3 · Cited by 24
Diabetes, Vascular Aging and Stroke: Old Dogs, New Tricks?
Penlioglou, T., Stoian, A. P., & Παπάνας, Ν. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194620 · Cited by 29
Neurohumoral stimulation in type-2-diabetes as an emerging disease concept
Pliquett, R., Faßhauer, M., Blüher, M., & Paschke, R. (2004) · Cardiovascular Diabetology · doi:10.1186/1475-2840-3-4 · Cited by 28
Yan, P., Zhu, X., Li, H., Shrubsole, M. J., Shi, H., Zhang, M., Harris, R. C., Hao, C., & Dai, Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037837 · Cited by 25
Nakao, Y. M., Teramukai, S., Tanaka, S., Yasuno, S., Fujimoto, A., Kasahara, M., Ueshima, K., Nakao, K., Hinotsu, S., Nakao, K., et al. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.11.025 · Cited by 24
Gerdts, E., Okin, P. M., Omvik, P., Wachtell, K., Dahlöf, B., Hildebrandt, P. R., Nieminen, M. S., & Devereux, R. B. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.12.009 · Cited by 24
Self-citationThe European Association for the Study of Diabetes
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1250 · Cited by 26
Treatment of isolated systolic hypertension in the elderly
Duprez, D. A. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.117 · Cited by 29
Preventing Macrovascular Disease in Patients with Type 2 Diabetes Mellitus
Johansen, O. E., & Birkeland, K. R. I. (2003) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200303040-00007 · Cited by 26
Épidémiologie des accidents vasculaires cérébraux
Béjot, Y., Caillier, M., Rouaud, O., Bénatru, I., Maugras, C., Osseby, G., & Giroud, M. (2007) · La Presse Médicale · doi:10.1016/j.lpm.2006.11.006 · Cited by 42
Burnier, M., Hess, B. J. M., Greminger, P., & Waeber, B. (2005) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-5-13 · Cited by 24
Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients
Hasegawa, H., Takano, H., Narumi, H., Ohtsuka, M., Mizuguchi, T., Namiki, T., Kobayashi, Y., & Komuro, I. (2011) · Hypertension Research · doi:10.1038/hr.2011.114 · Cited by 26
Chi, J. H., & Lee, B. J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262757 · Cited by 30
Goldstein, E. D., Wolcott, Z., Garg, G., Navarro, K., Delic, A., Yaghi, S. R., Sederholm, B., Prabhakaran, S., Wong, K.-H., McLean, K., et al. (2022) · Stroke · doi:10.1161/strokeaha.121.037997 · Cited by 23
da Silva, P. M. (2010) · Clinical Drug Investigation · doi:10.2165/11538440-000000000-00000 · Cited by 24
Sukumaran, V., Watanabe, K., Veeraveedu, P. T., Thandavarayan, R. A., Gurusamy, N., Ma, M., Yamaguchi, K., Suzuki, K., Kodama, M., & Aizawa, Y. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2010.010016 · Cited by 25
Villani, A. M., Clifton, P. M., & Keogh, J. B. (2012) · Journal of Human Nutrition and Dietetics · doi:10.1111/j.1365-277x.2011.01223.x · Cited by 26
Lip, S. Z. L., Jeemon, P., McCallum, L., Dominiczak, A. F., McInnes, G. T., & Padmanabhan, S. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv557 · Cited by 26
Preventing microalbuminuria in patients with type 2 diabetes
Jermendy, G., & Ruggenenti, P. L. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.693 · Cited by 32
Recommandations SFC/ALFEDIAM sur la prise en charge du patient diabétique vu par le cardiologue
Charbonnel, B. H., Bouhanick, B., & Feuvre, C. L. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(04)72798-6 · Cited by 25
Treatment of Systolic and Diastolic Heart Failure in the Elderly
Aronow, W. S. (2005) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2005.07.008 · Cited by 24
Berl, T., Hunsicker, L. G., & Lewis, J. B. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00276-9 · Cited by 24
Losartan and end-organ protection-lessons from the renaal study
Kowey, P. R., Dickson, T. Z., Zhang, Z., Shahinfar, S., & Brenner, B. M. (2005) · Clinical Cardiology · doi:10.1002/clc.4960280307 · Cited by 23
Insulin resistance and blood pressure
Addison, S. S., Stas, S. N., Hayden, M. R., & Sowers, J. R. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0059-1 · Cited by 27
Grenier, J., Goodman, S. G., Leiter, L. A., Langer, A., Teoh, H., Bhatt, D. L., CHENG, A. Y. Y., Tan, M., Ransom, T. P. P., Connelly, K. A., et al. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.01.005 · Cited by 22
Update on the Management of Hypertension for Secondary Stroke Prevention
Castilla‐Guerra, L., & Fernández‐Moreno, M. D. C. (2012) · European Neurology · doi:10.1159/000336836 · Cited by 21
Update on the Prevention of Type 2 Diabetes
Karam, J. G., & McFarlane, S. I. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0163-x · Cited by 28
Akbar, D. H., Hagras, M. M., Amin, H. A., & Khorshid, O. A. (2012) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320312460881 · Cited by 22
Fogari, R., Mugellini, A., Destro, M., Corradi, L., Lazzari, P., Zoppi, A., Preti, P. S., & Derosa, G. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03383.x · Cited by 24
Rahelić, D., Javor, E., Lucijanić, T., & Skelin, M. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1226514 · Cited by 26
Campbell, N. R. C., McAlister, F. A., Duong-Hua, M., & Tu, K. (2007) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(07)70827-9 · Cited by 27
Balamuthusamy, S., Molnár, J., Adigopula, S., & Arora, R. R. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31817fd87e · Cited by 22
Destro, M., Scabrosetti, R., Vanasia, A., & Mugellini, A. (2005) · Advances in Therapy · doi:10.1007/bf02850182 · Cited by 24
Rayner, B. L. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125002991 · Cited by 22
The Hypertension in Diabetes Study (HDS): a catalyst for change
Williams, B. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02506.x · Cited by 24
Comorbidity and Cardiovascular Risk Factors in Patients With Chronic Kidney Disease
Paparello, J. J., Kshirsagar, A. V., & BATLLE, D. C. (2002) · Seminars in Nephrology · doi:10.1053/snep.2002.35969 · Cited by 24
Nefropatia diabética e doença cardíaca
Gross, J. L., Silveiro, S. P., Canani, L. H. S., Friedman, R., Leitão, C. B., & de Azevedo, M. J. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000200013 · Cited by 26
Modulating atherosclerosis through inhibition or blockade of angiotensin
Rosenson, R. S. (2003) · Clinical Cardiology · doi:10.1002/clc.4950260703 · Cited by 22
Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes
Huerta, M. G., & Nadler, J. L. (2002) · Current Diabetes Reports · doi:10.1007/s11892-002-0103-5 · Cited by 25
Rosenson, R. S., & Reasner, C. A. (2004) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000133111.66486.c6 · Cited by 25
Schmieder, R. E. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000166826.17570.86 · Cited by 22
The ALLHAT study: if you believe in evidence-based medicine, stick to it!
Julius, S. (2003) · PubMed · doi:10.1097/01.hjh.0000052460.40108.69 · Cited by 22
Self-citationXie, X.-X., Liu, P., Wan, F.-Y., Lin, S.-G., Zhong, W.-L., Yuan, Z.-K., Zou, J.-J., & Liu, L.-B. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.01.197 · Cited by 21
Correlation between microalbuminuria and cardiovascular events.
Wang, Y., Yuan, A., & Chen, Y. (2013) · Europe PMC (PubMed Central) · Cited by 23
Yang, Y., & Xu, H. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13096 · Cited by 23
Formation of Protamine and Zn–Insulin Assembly: Exploring Biophysical Consequences
Aggarwal, S., Tanwar, N., Singh, A. K., & Munde, M. M. (2022) · ACS Omega · doi:10.1021/acsomega.2c04419 · Cited by 22
Alexander, N., Matsushita, K., Sang, Y., Ballew, S. H., Mahmoodi, B. K., Astor, B. C., & Coresh, J. (2015) · American Journal of Nephrology · doi:10.1159/000433450 · Cited by 19
Smink, P. A., Hoekman, J., Grobbee, D. E., Eijkemans, M. J. C., Parving, H.-H., Persson, F., Ibsen, H., Lindholm, L. H., Wachtell, K., de Zeeuw, D., et al. (2013) · European Journal of Preventive Cardiology · doi:10.1177/2047487313481754 · Cited by 24
Self-citationAraki, E., Tanaka, A., Inagaki, N., Ito, H., Ueki, K., Murohara, T., Imai, K., Sata, M., Sugiyama, T., Ishii, H., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0865 · Cited by 26
Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.54 · Cited by 24
Management of hypertension in patients with diabetes: the place of angiotensin‐II receptor blockers
Kalaitzidis, R., & Bakris, G. L. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01052.x · Cited by 22
Treatment of isolated systolic hypertension in diabetes mellitus type 2
Os, I., Gudmundsdottir, H., Kjeldsen, S. E., & Oparil, S. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00523.x · Cited by 21
Self-citationPrevention of cardiovascular disease: an evidence‐based clinical aid 2004
Fulcher, G., Conner, G. W., & Amerena, J. V. (2004) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2004.tb06317.x · Cited by 22
Katsiki, N., Tsioufis, K. P., Ural, D., & Volpe, M. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13325 · Cited by 20
Verdecchia, P., & Angeli, F. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90049-5 · Cited by 25
The Effect of Diabetes on B-Type Natriuretic Peptide Concentrations in Patients With Acute Dyspnea
Wu, A. H. B., Omland, T., Duc, P., McCord, J., Nowak, R. M., Hollander, J. E., Herrmann, H. C., Steg, P. G., Knudsen, C. W., Storrow, A. B., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2398 · Cited by 23
Julius, S., Kjeldsen, S. E., Brunner, H. R., Ekman, S., Laragh, J. H., Stolt, P., McInnes, G. T., Smith, B. A., Plat, F., Schork, M. A., et al. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-0258-5.50122-8 · Cited by 21
Self-citationJaroudi, W. A. A., Nuwayri‐Salti, N., Usta, J. A., Zwainy, D. S., Karam, C. N., Bitar, K. M., & Bikhazi, A. B. (2005) · Journal of Hypertension · doi:10.1097/00004872-200502000-00021 · Cited by 21
Chazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Владимировна, А. А., Alekseeva, T. A., Ambatiello, L. G., Balanova, Y. А., Bragina, A. E., Danilov, N. M., Drapkina, O. M., et al. (2024) · Systemic Hypertension · doi:10.38109/2075-082x-2024-4-5-109 · Cited by 28
Sim, M., Xu, X.-G., Wong, Y.-C., Sim, S.-Z., & Lee, K. (2007) · Endocrinology · doi:10.1210/en.2007-0606 · Cited by 20
Slowing progression along the renal disease continuum.
Kopyt, N. P. (2005) · PubMed · Cited by 25
The Role of Renin-Angiotensin Agents in Altering the Natural History of Type 2 Diabetes Mellitus
Lardizabal, J. A., & DEEDWANIA, P. C. (2010) · Current Cardiology Reports · doi:10.1007/s11886-010-0138-1 · Cited by 24
Sun, H. Q., Zhao, Y., Bi, X., Li, S., Su, G., Miao, Y., Ma, X., Zhang, Y., Zhang, W., & Zhong, M. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0246-8 · Cited by 20
Salum, E., Butlin, M., Kals, J., Zilmer, M., Eha, J., Avolio, A. P., Arend, A., Aunapuu, M., & Kampus, P. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-57 · Cited by 26
Cloutier, L., & Lamarre-Cliché, M. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.01.012 · Cited by 22
Candesartan Improves Ischemia-Induced Impairment of the Blood–Brain Barrier In Vitro
So, G., Nakagawa, S., Morofuji, Y., Hiu, T., Hayashi, K., Tanaka, K., Suyama, K., Deli, M. A., Nagata, I., Matsuo, T., et al. (2014) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-014-0152-8 · Cited by 21
Pathophysiology of Antihypertensive Therapy with Diuretics
Fukuda, M., & Kimura, G. (2006) · Hypertension Research · doi:10.1291/hypres.29.645 · Cited by 21
Konstam, M. A., Poole-Wilson, P. A., Dickstein, K., Drexler, H., Justice, S. J., Michel Komajda, N., Malbecq, W., Martínez, F. A., Neaton, J. D., Riegger, G. A. J., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.07.004 · Cited by 20
Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities.
Khamaisi, M., Wexler, I. D., Škrha, J., Strojek, K., Raz, I., & Miličević, Z. (2003) · PubMed · Cited by 26
Should albuminuria be a therapeutic target in patients with hypertension and diabetes?
de Zeeuw, D. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.08.005 · Cited by 22
Beneficial Effect of Candesartan on Rat Diastolic Heart Failure
Wake, R., Kim‐Mitsuyama, S., Izumi, Y., Yoshida, K., Izumiya, Y., Yukimura, T., Shiota, M., Yoshiyama, M., Yoshikawa, J., & Iwao, H. (2005) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fp0050160 · Cited by 21
Therapy Insight: management of cardiovascular disease in the renal transplant recipient
Rigatto, C., & Parfrey, P. S. (2006) · Nature Reviews Nephrology · doi:10.1038/ncpneph0253 · Cited by 21
Jacob, S., & Henriksen, E. J. (2004) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2004.03704.x · Cited by 22
Creating a Combination Antihypertensive Regimen: What Does the Research Show?
Weber, M. A. (2003) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2003.02674.x · Cited by 20
Metadata
- Authors
- Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., Lederballe-Pedersen, O., Nieminen, M. S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J., & Snapinn, S.
- Affiliations
- University Hospital of Umeå (SE)
- Glostrup Hospital (DK)
- Sahlgrenska University Hospital (SE)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- University of Michigan (US)
- Oslo University Hospital (NO)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Lindholm, Lars H
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 1004-1010
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W1982920623
- Cited by
- 1,560
- References
- 31
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 8 · 2023: 15 · 2022: 17 · 2021: 18 · 2020: 29 · 2019: 16 · 2018: 28 · 2017: 40 · 2016: 40 · 2015: 41 · 2014: 48 · 2013: 58 · 2012: 58
- FWCI
- 129.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- losartan, atenolol, hypertension, diabetes mellitus, left ventricular hypertrophy, cardiovascular morbidity, cardiovascular mortality, antihypertensive drugs, ACE inhibitors, beta-blockers, LIFE trial, stroke, myocardial infarction, all-cause mortality, blood pressure reduction, Framingham risk score, electrocardiogram
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypertension, Male, Middle Aged, Regression Analysis, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.